Synsorb has the patent! Sell your house! Sell your dog! Buy syb.
Well, maybe. The news looks good. I guess I thought they had some protection already, where the 1994 Ann.Report p.3 mentions "Synsorb technology has been extensively patented."
Also refer to US patent 5484773, "treatment of antibiotic associated diarrhea", granted to Synsorb, per Jan 16 96 press release. Relates to CDAD.
The new patent, 5620858, relates to Synsorb Pk, HUS.
----
To:
fbealle@idirect.com
First US patent for Synsorb Pk
Synsorb Biotech Inc
SYB
Shares issued 16,084,520 Apr 21 close
$9.40
Tue 22 Apr 97 News
Release
Mr David Rafter reports
The US Patent and Trademark Office has issued patent 5,620,858, to
the
company effective April 15 1997. The patent, issued in the US,
covers the
use of Synsorb Pk in the neutralization of verotoxins secreted by
the
bacterium E. coli O157:H7 which cause Hemolytic Uremic Syndrome.
E. coli O157:H7 is a particularly virulent strain of bacteria,
found in
contaminated meat, vegetables, dairy products and ground water. The
disease
is a leading cause of both acute and chronic renal
insufficiency in
children and is recognized as one of the fastest growing
foodborne
infectious diseases in the world. Synsorb Pk is a potential treatment
for
the prevention of Hemolytic Uremic Syndrome (HUS), one of the most
serious
complications resulting from E. coli O157:H7 infections.
This patent substantially enhances the company's proprietary position
with
respect to Synsorb Pk.
Synsorb Biotech is developing therapeutic products for
gastrointestinal
diseases which at present have no cure or would benefit from
alternate
therapies. In addition to Synsorb Pk for E. coli infections, the
company
has a full suite of orally delivered gastroenteric products
under
development. These include a treatment for recurring or
relapsing
antibiotic associated diarrhea (CDAD) which will begin a phase II
clinical
trial in May 1997, as well as potential drug candidates for
Traveller's
Diarrhea and infant diarrhea.
Synsorb Biotech is currently conducting a phase III clinical
trial in
Canada to investigate Synsorb Pk's effectiveness in preventing
kidney
damage in children with E. coli O157:H7 infections. The company
plans to
initiate a phase III study for the same indication in the US in
1997. A
National Institutes of Health (NIH) sponsored phase III trial in the
US for
a second indication for Synsorb Pk will also begin in 1997. |
